Document is current

Article History

Received: 27 August 2021

Accepted: 30 June 2022

First Online: 14 July 2022

Declarations

:

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the University of British Columbia/Providence Health Care Research Ethics Board (H17-01794) and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

: The authors certify that the enclosed manuscript is not being considered for publication elsewhere; all authors have reviewed and approved the manuscript for submission for publication.

: Dr. Le Foll has obtained funding from Pfizer (GRAND Awards, including salary support) for investigator-initiated projects. Dr. Le Foll has some in-kind donation of cannabis product from Aurora and medication donation from Pfizer and Bioprojet and was provided a coil for TMS study from Brainsway. Dr. Le Foll has obtained industry funding from Canopy (through research grants handled by Centre for Addiction and Mental Health [CAMH] or University of Toronto), Bioprojet, American Chemical Society (ACS) and Alkermes. Dr. Le Foll has received in-kind donations of nabiximols from GW Pharma for past studies funded by CIHR and the National Institutes for Health (NIH). He has been consultant for Shionogi. No other authors have relevant financial or non-financial interests to disclose.